Skip to content

Switching from Mounjaro to Zepbound

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Switching from Mounjaro to Zepbound means moving between two brands of tirzepatide, each with its own label and approved uses. Neither label gives steps for moving between them, and the Zepbound label says using it with other tirzepatide-containing products isn't recommended. Its stated starting dose is 2.5 mg once weekly. Self-pay Zepbound vials cost $299 to $449 a month.

Source: LillyDirect self-pay

Key takeaways

  • Both brands contain tirzepatide, but a pharmacist can't swap one for the other. You need a new prescription.
  • Neither label says how to move between them. Zepbound's starting dose is 2.5 mg once weekly. Your prescriber sets yours.
  • Zepbound's label says using it with another tirzepatide product, Mounjaro included, isn't recommended.
  • Paying cash through LillyDirect? Mounjaro is $499 a month. Zepbound vials cost less if refilled on time.
  • On Medicare with type 2 diabetes? You aren't eligible for Zepbound through the GLP-1 Bridge.

What the labels say about switching from Mounjaro to Zepbound

The Zepbound label gives one starting dose for everyone: 2.5 mg once weekly. It gives no dose conversion from Mounjaro.

The recommended starting dosage of ZEPBOUND for all indications is 2.5 mg injected subcutaneously once weekly for 4 weeks. The 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage.
  • The Zepbound label gives no instructions for switching from another GLP-1 medicine; it only gives the starting dose (2.5 mg once weekly).

    FDA label: Revised: 8/2026 (DailyMed version 40)

  • The Zepbound label says using Zepbound together with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.

    ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.

    FDA label: Revised: 8/2026 (DailyMed version 40)

Cheapest verified self-pay price, before and after the switch
How you payPer fill
Mounjaro 15 mgLillyDirect self-pay$499
Zepbound 2.5 mgMeasured$348

Try other combinations in the switching planner. Switching is a prescriber decision.

Mounjaro and Zepbound are both tirzepatide injections made by Eli Lilly, and they come in the same strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Each has its own label and its own approved uses. Mounjaro is approved to improve blood sugar control in type 2 diabetes, and to reduce cardiovascular risk in adults with type 2 diabetes who are at high risk. Zepbound is approved for long-term weight reduction, and for moderate to severe obstructive sleep apnea in adults with obesity.

Because the two brands are regulated as separate products, a pharmacist can’t give you one in place of the other. To change, you need a new prescription written for the new brand.

What the two labels say

Less than you might expect for two products with the same ingredient.

The Zepbound label gives no steps for switching from another medicine, Mounjaro included. It gives only its starting dose. The Mounjaro label gives no switching steps either. Each label does say something about changing form (vial, single-dose pen, KwikPen), but only within that one brand: if your prescribed form changes, you should be trained on the new one and read its Instructions for Use. That text isn’t about moving from one brand to the other.

One limitation of use applies directly. The Zepbound label says it contains tirzepatide, and that using it with other tirzepatide-containing products isn’t recommended.

What dose does the Zepbound label state?

The recommended starting dose for all uses is 2.5 mg once weekly for 4 weeks, then 5 mg. After that, the dose can go up in 2.5 mg steps after at least 4 weeks on the current dose. For weight reduction, the label’s maintenance doses (the doses you stay on) are 5 mg, 10 mg or 15 mg. For sleep apnea they’re 10 mg or 15 mg.

The label doesn’t say what should happen for someone who is already settled on a Mounjaro strength. We report the label as written and leave the dose to your prescriber.

Cost: the brands are priced differently

Both are sold through LillyDirect, at different prices:

  • Mounjaro single-dose pens: $499 a month self-pay at every strength.
  • Zepbound single-dose vials or KwikPen: $299 at 2.5 mg, $399 at 5 mg, and $449 from 7.5 mg to 15 mg if you buy each refill within 45 days. A late 7.5 mg refill is $499, and a late refill at 10 mg or above is $699.

For the Zepbound single-dose pen, the prices come from the savings card: $25 if your commercial plan covers it, or $499 a month if your commercial plan doesn’t. If you’ve only used Mounjaro pens, keep in mind that a Zepbound vial means drawing up each dose with a syringe, using a new syringe and needle every time. The Zepbound cost page and the 45-day rule have the details.

Your Mounjaro savings card doesn’t work for Zepbound. The Zepbound card is a separate sign-up.

Coverage: the diagnosis decides

An insurer that covers Mounjaro is covering treatment for type 2 diabetes. A Zepbound claim gets reviewed under the plan’s rules for weight management or sleep apnea, with a new prior authorization (the plan’s approval before it pays). A plan can also exclude weight-loss drugs altogether.

On Medicare, CMS lists type 2 diabetes and moderate to severe obstructive sleep apnea as uses that can be covered under Part D, while the law excludes drugs when they’re used for weight loss. The GLP-1 Bridge covers the Zepbound KwikPen for weight management. But people with type 2 diabetes aren’t eligible, and neither is anyone who got a GLP-1 through Part D in 2026. If you take Mounjaro for type 2 diabetes and you’re on Medicare, that rules out the Bridge.

Questions for the appointment

  • What is the Zepbound prescription for, and does your plan cover that use?
  • If you have type 2 diabetes, how will your blood sugar be managed, since Zepbound’s approved uses don’t include it?
  • Which form will you use: vial, single-dose pen or KwikPen?
  • Which dose is being prescribed, and on what date does it start?

Compare the two brands’ prices in the cost calculator, or check other pairs in the switching planner.

Frequently asked questions

Can I stay on my current dose when I switch from Mounjaro to Zepbound?

The labels don't say. Mounjaro and Zepbound come in the same six strengths, but the Zepbound label has no steps for people coming from Mounjaro. It states a starting dose of 2.5 mg once weekly. Whether your prescription stays at the strength you take now is a decision only your prescriber can make.

Can I use up my Mounjaro pens after starting Zepbound?

The Zepbound label says using it together with other tirzepatide-containing products isn't recommended, and Mounjaro is one of them. The two aren't meant to overlap. Ask your prescriber which fill should be your last Mounjaro and when your first Zepbound dose falls. Ask your pharmacist how to get rid of any pens left over.

Is Zepbound cheaper than Mounjaro for cash payers?

On self-pay prices, yes, if you use vials or the KwikPen. Mounjaro pens are $499 a month through LillyDirect at every strength. Zepbound vials are $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 mg and above when you refill within 45 days.

Why would my doctor switch me from Mounjaro to Zepbound?

A common reason is the use the prescription is written for. Mounjaro is approved for type 2 diabetes. Zepbound is approved for long-term weight reduction, and for moderate to severe obstructive sleep apnea in adults with obesity. Lilly's savings card terms require a prescription for an approved use that matches the label, so the brand tends to follow the condition being treated.

Sources (10)

  1. 1.
    FDA label (DailyMed): Zepbound prescribing information, section 1
    “ZEPBOUND contains tirzepatide. Coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended.”
  2. 2.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Inform patients and their caregiver(s) which ZEPBOUND presentation (e.g., vial, prefilled single-dose pen, single-patient-use KwikPen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed ZEPBOUND presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.”
  3. 3.
    FDA label (DailyMed): Zepbound prescribing information, section 2.4
    “Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
  4. 4.
    FDA label (DailyMed): Zepbound prescribing information, section 2.2
    “The recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.”
  5. 5.
    Federal Register: Medicare and Medicaid Programs; Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (proposed rule, 89 FR 99340)
    “The statutory definition of a covered Part D drug at section 1860D-2(e)(2) of the Social Security Act (the Act) excludes certain drugs and uses—specifically, those that may be excluded by Medicaid under section 1927(d)(2) of the Act. This includes, at section 1927(d)(2)(A) of the Act, “agents when used for anorexia, weight loss, or weight gain.” Historically, drugs used for weight loss have been excluded from the definition of covered Part D drug, regardless of their use for treatment of individuals with obesity, and have been an optional drug benefit for Medicaid programs.”
  6. 6.
    CMS: Information for Part D Plans
    “Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. [...] If a Medicare Part D beneficiary has a prescription for a GLP-1 drug for an indication covered under Medicare Part D, they should continue to obtain their GLP-1 through their Part D plan.”
  7. 7.
  8. 8.
  9. 9.
  10. 10.